The phosphoinositide 3-kinase (PI3-kinase)-protein kinase B (Akt) signaling pathway is essential in the induction of physiological cardiac hypertrophy. In contrast, protein kinase C ␤2 (PKC␤2) is implicated in the development of pathological cardiac hypertrophy and heart failure. Thus far, no clear association has been demonstrated between these two pathways. In this study, we examined the potential interaction between the PI3-kinase and PKC␤2 pathways by crossing transgenic mice with cardiac specific expression of PKC␤2, constitutively active (ca) PI3-kinase, and dominant-negative (dn) PI3-kinase. In caPI3-kinase/PKC␤2 and dnPI3-kinase/PKC␤2 double-transgenic mice, the heart weight-tobody weight ratios and cardiomyocyte sizes were similar to those observed in caPI3-kinase and dnPI3-kinase transgenic mice, respectively, suggesting that the regulation of physiological developmental hypertrophy via modulation of cardiomyocyte size proceeds through the PI3-kinase pathway. In addition, we observed that caPI3-kinase/ PKC␤2 mice showed improved cardiac function while the function of dnPI3-kinase/PKC␤2 mice was similar to that of the PKC␤2 group. PKC␤2 protein levels in both dnPI3-kinase/PKC␤2 and PKC␤2 mice were significantly upregulated. Interestingly, however, PKC␤2 protein expression was significantly attenuated in caPI3-kinase/PKC␤2 mice. PI3-kinase activity measured by Akt phosphorylation was not affected by PKC␤2 overexpression. These data suggest a potential interaction between these two pathways in the heart, where PI3-kinase is predominantly responsible for the regulation of physiological developmental hypertrophy and may act as an upstream modulator of PKC␤2 with the potential for rescuing the pathological cardiac dysfunction induced by overexpression of PKC␤. transgenic mice; constitutive active; dominant negative; protein kinase B THE PHOSPHOINOSITIDE 3-kinases (PI3-kinases) generate lipids controlling an assortment of intracellular signaling pathways and having many diverse roles, including membrane trafficking along the endocytic pathway, cytoskeletal organization, adhesion, cell growth, and apoptosis (4, 8, 28, 29) . Studies with transgenic (Tg) mice exhibiting heart-specific expression of constitutively active (caPI3-kinase) or dominant-negative (dnPI3-kinase) mutants have shown that PI3-kinase overexpression results in increased heart weight because of an increase in cardiomyocyte size, whereas dnPI3-kinase mice showed a decrease in heart size that correlated with a decrease in cardiomyocyte size (25). These data indicate that, for the heart, as in other systems, the PI3-kinase pathway is necessary for organ growth. PI3-kinase (p110␣) has also been shown to be involved in the induction of exercise-induced physiological, but not pressure overload-induced pathological, cardiac hypertrophy (20, 22) .
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A pathway that is generally associated with pathological or maladaptive hypertrophy is protein kinase C (PKC), which consists of a family of serine-threonine kinases. To date, at least 11 isoforms of PKC have been discovered, and several of these isoforms, specifically PKC␣, -␤, -ε, and -, have been widely studied for their mechanistic role in the cardiovascular system (23, 31) . Heart failure, for example, which is often characterized by hypertrophy and a loss of cardiac function, is associated with an elevation in PKC␣ protein content and activity (1, 3) . On the other hand, the role of PKC␤2 in cardiac hypertrophy and heart failure is not well defined. Overexpression of the PKC␤2 isoform in the Tg mouse heart leads to cardiac hypertrophy, fibrosis, and cell death, providing evidence that PKC␤2 is also involved in the structural and functional changes observed in pathological hypertrophy and heart failure (30) . It has also been reported that overexpression of activated PKC␤2 causes induction of the promoters of ␤-myosin heavy chain (MHC) and skeletal ␣-actin, two marker genes for transcriptional signaling in hypertrophy (17, 18) .
We therefore explored the potential interaction between the physiological PI3-kinase pathway and the pathological PKC␤2 pathway by crossing Tg mice with heart-specific PI3-kinase activation and PKC␤2 overexpression. We analyzed the effect of modulating the expression of these two pathways on the heart, specifically focusing on cardiomyocyte size and cardiac function.
MATERIALS AND METHODS
Generation of Tg mice. caPI3-kinase and dnPI3-kinase Tg mice were produced by inserting the cDNA for iSH2p110 (with the Myc epitope tag) or a catalytically inactive p110 molecule (with a FLAG epitope tag) in the murine ␣-MHC promoter construct as described previously (25) . The iSH2p110 gene is a chimeric molecule that contains the iSH2 domain of p85 fused to the NH 2 terminus of bovine p110␣ by a flexible glycine linker that has been shown to function as a constitutively active molecule (9, 13) . A catalytically inactive p110 molecule has a truncated p110 mutant that has p85 binding domains but lacks the kinase domain (p110kinase). It therefore competes with endogenous p110 for interaction with the p85 regulatory subunit and has an inhibitory effect on the function of the endogenous p110 molecule (33) . PKC␤2 Tg mice were generated by inserting a 2.1-kb BamHI fragment of mouse PKC␤2 cDNA in the 3.3-kb EagI-SalI Fig. 1 . Comparison of organ weights and cardiomyocyte size in transgenic (Tg) mice. A: representation of heart size from wild-type (WT), protein kinase C (PKC) ␤2, dominant-negative (dn) phosphatidylinositol 3-kinase [PI3-kinase (PI3K)], constitutively active (ca) PI3-kinase dnPI3-kinase/PKC␤2, and caPI3-kinase/PKC␤2 mice. The spacing between any two lines on the ruler is 1 mm. B: representative images of dissociated cardiomyocytes. Images were taken with a ϫ40 magnification. Scale bar ϭ 100 m. C: quantitative analysis of mean area of cardiomyocytes for each group (m 2 ); n ϭ 300 cells. P Ͻ 0.05 compared with WT (*) and compared with PKC␤2 ( †). NS, not significant. fragment of the plasmid containing rat MHC (␣-MHC) promoter as previously described (30) . Mice used in this study were of the FVB genetic background. All aspects of animal care and the experimental protocols used in this study were approved by the Institutional Animal Care and Use Committee of the Beth Israel Deaconess Medical Center.
Echocardiography. The procedure was performed in 12-to 14-wkold male mice as described previously (21, 22, 25) . Briefly, after anesthesia with an isoflurane inhalant, echocardiography was performed with a Hewlett-Packard Sonos Agilent 5500 sector scanner equipped with a 15-MHz linear-array transducer. Anterior and posterior wall thickness and left ventricle (LV) internal dimensions were measured according to the leading-edge method of the American Society of Echocardiography (24) .
Morphometric analysis of isolated cardiomyocytes. Cardiomyocytes were enzymatically dissociated from the mouse heart according to the previously described protocol (21, 25) . The hearts from 12-to 14-wk-old male Tg or wild-type (WT) mice were retrogradely perfused with 0.3% collagenase (Worthington). The dissociated cardiomyocytes were plated on laminin (10 g/ml)-coated dishes. After 1 h of plating, unattached cells were removed by changing the media. Photographs were taken under a phase-contrast microscope, and cell surface area was determined by using the GNU Image Manipulation Program (GIMP 2.2.13) software (Open Source). Approximately 200 cells for each heart were measured, and the mean values for each heart were used for the statistical analysis.
Immunoblotting. Immunoblotting was performed as described previously (21, 22, 25) . Protein concentration of whole heart tissue lysate was determined by the Bradford method (Bio-Rad), and glyceraldehyde-3-phosphate dehydrogenase (1:5,000) (RDI) was used as a loading control. Antibodies were diluted as follows: PKC␤2 (Santa Cruz), Akt (1:1,000; Cell Signaling), phospho-Akt (1:1,000; Cell Signaling).
Fractionation of whole heart tissue. The hearts from 12-to 14-wkold, male, WT, and Tg mice were snap-frozen in liquid nitrogen and homogenized in ice-cold 20 mM Tris ⅐ HCl (pH 7.5), 2 mM EDTA, 0.5 mM EGTA, 1 mM phenylmethlysulfonyl fluoride, 1 mM dithiothreitol, 0.3 M sucrose, and 25 g/ml leupeptin (buffer A) with a Polytron electric homogenizer for 20 s and then with a Dounce homogenizer (60 strokes). The homogenates were centrifuged at 2,500 revolutions/ min (rpm) for 10 min at 4°C, and the supernatant was ultracentrifuged at 40,000 rpm for 30 min at 4°C. The resulting supernatant was retained as the cytosolic fraction, and the pellets were resuspended with buffer A without sucrose (buffer B) and solubilized with 1% Triton X-100. After being rotated for 45 min at 4°C, soluble membrane fractions were obtained by ultracentrifugation at 40,000 rpm for 30 min. The membrane pellet was resuspended in buffer B by Dounce homogenization. PKC␤2 expression levels in the cytosol and membrane fractions were shown by Western blot.
Histology. Hearts were fixed in 10% formalin and paraffin-embedded. Sections were stained with hematoxylin and eosin and Masson Trichrome (MT) at the Histology Core facility at Beth Israel Deaconess Medical Center. Fibrosis was quantified at ϫ20 using a calibrated digital camera and software (DP 70 and DPController; Olympus America, Irving, TX) to survey entire heart sections. All areas of fibrosis were scored as either major (MT staining consisting of Ͼ10%/visual field) or minor (MT staining in Ͻ10%/visual field or presence of perivascular fibrosis).
RT-PCR analysis for PKC␤2 mRNA expression. Total RNA was extracted from mouse ventricular tissue using TRIzol (GIBCO-BRL, Gaithersburg, MD). RT-PCR was performed by PCR amplification of cDNA reverse transcribed from mRNA using mouse PKC␤2 and 18S primers. The following primer sequences were used: PKC␤2 primer, forward 5Ј-ATTCCAGTGTCAAGTCTGCT and reverse 5Ј-CCCAT-GAAGTCATTCCTGCT; 18S primer, forward 5Ј-GTTATGGTTCC TTTGTCGCTCGCTC and reverse 5Ј-TCGGCCCGAGGTTATCTA-GAGTCAC.
Adult rat cardiomyocyte culture. Adult rat cardiomyocyte cultures were prepared from the hearts of female Sprague-Dawley rats using retrograde perfusion with 0.3% collagenase (Worthington Biochemical, Lakewood, NJ) as described previously (2, 11, 16) .
Statistical analysis. All data were expressed as means Ϯ SE. Between-group and among-group comparisons were conducted with unpaired Student's t-tests and ANOVAs, respectively. P values of Ͻ0.05 were considered significant.
RESULTS

PI3-kinase regulates heart weight-to-body weight ratio in double-Tg mice.
Tg caPI3-kinase mice showed a significant increase in the heart weight-to-body weight (HW/BW) ratio of ϳ41% compared with WT, whereas dnPI3-kinase mouse Values are means Ϯ SE. WT, wild type; PKC, protein kinase C; dn, cominant negative; ca, constitutively active; PI3K, phosphoinositol 3-kinase; TL, tibial length; HW/BW, heart weight-to-body weight ratio; HW/TL, heart weight-to-tibial length ratio. P Ͻ 0.05 compared with WT (*) and compared with PKC ( †). Values are means Ϯ SE; n, no. of animals. HR, heart rate; IVSd, intraventricular septum in diastole; LVIDd, left ventricular internal diameter in diastole; LVPWd, left ventricular posterior wall in diastole; FS, fractional shortening. P Ͻ 0.05 compared with WT (*) and compared with PKC ( †).
hearts were significantly smaller (14%) than hearts of WT littermates (Fig. 1A and Table 1 ). PKC␤2 mice showed an increase (19%) in HW/BW ratio compared with WT controls. In crossing experiments, caPI3-kinase/PKC␤2 double-Tg mice exhibited an increase in HW/BW ratio similar to that of caPI3-kinase mice compared with WT mice, whereas dnPI3-kinase/PKC␤2 double-Tg mice displayed a 16% decrease in HW/BW ratio compared with WT mice. Thus the HW/BW ratios observed in double-Tg mice were similar to those of either caPI3-kinase or dnPI3-kinase, respectively (Fig. 1A and Table 1 ). The heart weight to tibia length ratios followed the same pattern as HW/BW ratios. However, as we have observed previously, the lung weight-to-body weight ratio did not differ significantly among the groups (22, 25) . These findings suggest that the PI3-kinase pathway is dominant in the regulation of physiological developmental hypertrophy, whereas PKC␤2 does not appear to play a significant role in this process.
PI3-kinase pathway dominates in the regulation of cardiomyocyte size in the presence of PKC␤2. To determine whether the differences in heart size in the Tg mice are related to changes in cardiomyocyte size, we measured the surface area of dissociated cells from each of the genetically altered mouse groups. We found that caPI3-kinase mice exhibit an increase (19%) whereas dnPI3-kinase mice exhibit a decrease (18%) in mean cell area compared with WT controls; these data are consistent with our previous report (Fig. 1, B and C, and Ref. 25) . We also found that cardiomyocyte cell size was not increased in PKC␤2 mice, suggesting that the increase observed in the HW/BW ratio is most likely the result of an increase in fibrosis or nonmyocyte cellular proliferation. Fig. 2 . Comparison of the amount of cardiac fibrosis in Tg mice heart. A: representative image of Masson Trichrome staining in heart tissue sections of WT, PKC␤2, and caPI3-kinase/PKC␤2 Tg mice hearts. B: quantitative analysis of fibrosis in Tg mice hearts; n ϭ 4 animals/group, P Ͻ 0.05 compared with WT (*) and compared with PKC␤2 ( †). ND, not detected. Fig. 3 . PKC␤2 protein expression level in the hearts of Tg mice. A: Western blot of the cytosol and membrane fractions of whole heart tissue of PKC␤2 mice probed with anti-PKC␤2 antibody. B: representative Western blot of whole heart lysate probed with anti-PKC␤2 antibody (82 kDa) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control (37 kDa). C: representative PCR of PKC␤2 mRNA expression from WT, PKC␤2, and caPI3-kinase/PKC␤2 Tg mice hearts. 18S RNA is shown as the internal loading control. D: representative Western blot of PKC␤2 (top) and GAPDH control (bottom) in adult cardiomyocyte cultures with or without insulin (100 nM) for 3 days. E: quantitative analysis of PKC␤2 protein level in adult cardiomyocytes with or without insulin; n ϭ 4 different animals. *P Ͻ 0.05 compared with control.
Among the double-Tg groups, caPI3-kinase/PKC␤2 mice showed a mean cell area comparable to caPI3-kinase littermates, and the mean cell area in dnPI3-kinase/PKC␤2 mice was comparable to dnPI3-kinase. From these findings, we conclude that the PI3-kinase pathway dominates in the regulation of physiological developmental hypertrophy by directly controlling the size of cardiomyocytes.
caPI3-kinase rescues cardiac function. Next, we used echocardiography to assess cardiac function in double-Tg mice. There was a significant increase in intraventricular septum wall thickness in caPI3-kinase (27%) and caPI3-kinase/PKC␤2 Tg mice (40%) compared with the WT group (Table 2 ), but the difference between caPI3-kinase and caPI3-kinase/PKC␤2 Tg mice was not significant. Left ventricular posterior wall in diastole did not differentiate the groups either (0.84 mm for both), suggesting that there is no synergistic increase in LV wall thickness in double-Tg mice. LV systolic performance was measured by assessing the mean fractional shortening (FS) of each group. FS in caPI3-kinase and dnPI3-kinase mice did not differ from WT littermates. In contrast, PKC␤2 mice showed a decrease in cardiac function, as reported previously (30) . Interestingly, cardiac performance in caPI3-kinase/PKC␤2 mice was improved significantly (44%) compared with PKC␤2 mice (Table 2 ). On the other hand, FS in dnPI3-kinase/PKC␤2 mice decreased (14%) and was similar to that of PKC␤2 mice. These findings indicate that the decreased heart function in PKC␤2 mice may be restored by an increase in the expression level of PI3-kinase in caPI3-kinase/ PKC␤2 double-Tg animals.
Because the deterioration of cardiac function seen in PKC␤2 mice may be related to increased fibrosis, we investigated the presence of cardiac fibrosis using MT staining of the heart tissue sections. We found that PKC␤2 Tg mice showed a significant increase in MT staining, suggesting increased fibrosis (Fig. 2, A and B) . In contrast, caPI3-kinase/PKC␤2 double-Tg mice showed a significant decrease in cardiac fibrosis compared with PKC␤2 Tg mice, suggesting that the overexpression of caPI3-kinase suppressed the cardiac fibrosis observed in PKC␤2 Tg mice.
PI3-kinase regulates PKC␤2 expression. To determine the potential mechanism of improved cardiac function, we compared PKC␤2 expression levels among different Tg mice. PKC␤2 mice, as expected, exhibited a high expression level compared with WT, dnPI3-kinase, and caPI3-kinase mice (29-, 71-, and 59-fold increase, respectively). We also observed translocation of PKC␤2 to the membrane, suggesting PKC␤2 activation (Fig. 3A) . In dnPI3-kinase/PKC␤2 mice, the expression level of PKC␤2 was comparable to the protein expression level found in PKC␤2 mice and significantly higher than in WT mice. Surprisingly, the PKC␤2 protein level was completely suppressed in caPI3-kinase/PKC␤2 mice, and it was similar to the baseline level found in WT mice (Fig. 3B) . Furthermore, the mRNA expression level of PKC␤2 was also significantly decreased in caPI3-kinase/PKC␤2 double-Tg mice (Fig. 3C) . Finally, we verified that PKC␤2 expression is regulated by PI3-kinase endogenously, using insulin to activate PI3-kinase in adult rat cardiomyocyte cultures. Activating PI3-kinase signaling with insulin significantly suppressed endogenous PKC␤2 (Fig. 3, D and E) . These data support the previous results indicating that transcriptional repression of PKC expression in the caPI3-kinase/PKC␤2 double-Tg mouse heart significantly downregulates the expression of PKC␤.
PKC␤2 does not alter PI3-kinase activity.
To determine whether the overexpression of PKC␤2 in caPI3-kinase/PKC␤2 mice affects the PI3-kinase-protein kinase B (Akt) pathway, we measured the phosphorylation of Akt, which has been used extensively as evidence of PI3-kinase activity, in all studied groups using a phosphospecific antibody. There was no significant activation of Akt phosphorylation in PKC␤2 Tg mice, suggesting that PKC␤2 by itself does not alter PI3-kinase activity at baseline (Fig. 4, A and B) . However, we observed, as expected, that the level of phosphorylated Akt was significantly higher in caPI3-kinase than in WT mice. This increased Akt phosphorylation was not changed significantly in caPI3-kinase/PKC␤2 mice compared with caPI3-kinase (Fig. 4, A and  B) . These data suggest that the protein level of Akt, a downstream target of PI3-kinase, was not altered significantly by overexpression of PKC␤2 in the double-Tg animals. Thus PKC␤2 does not appear to regulate PI3-kinase expression and is most likely a downstream target of PI3-kinase. A: representative Western blot of whole heart lysate probed with phosphorylated protein kinase B (Akt), total Akt (60 kDa), and GAPDH as a loading control. B: quantification of phosphorylated Akt normalized to total Akt and GAPDH (arbitrary units); n ϭ 3-6 animals. P Ͻ 0.05 compared with WT (*) and compared with PKC␤2 ( †).
DISCUSSION
In this study, we examined potential interactions between the PI3-kinase and PKC␤2 pathways by crossing Tg mice with cardiac specific expression of caPI3-kinase, dnPI3-kinase, and PKC␤2. First, we found that the PI3-kinase pathway dominates in the regulation of physiological developmental hypertrophy by directly controlling the size of cardiomyocytes. Second, caPI3-kinase was able to rescue the cardiac dysfunction of PKC␤2 mice, suggesting that activation of the PI3-kinase pathway can overcome the deleterious effect of PKC␤2 in the heart. Finally, we show for the first time that there may be an interaction between the PI3-kinase and PKC␤2 pathways and that PI3-kinase is most likely an upstream regulator of PKC␤2.
Our study further supports the notion that class IA PI3-kinases are critical regulators for the developmental growth and physiological hypertrophy of the heart (20) . Cardiomyocyte sizes in double-Tg caPI3-kinase/PKC␤2 and dnPI3-kinase/PKC␤2 mice were comparable to those found in caPI3-kinase or dnPI3-kinase littermates, respectively. However, despite increased heart weight, cardiomyocyte size in PKC␤2 mice was similar to that found in the WT control group. We thus infer that PKC␤2 is not involved in the regulation of physiological developmental hypertrophy. The observed increase in HW/BW ratio is most likely because of cardiac fibrosis. Indeed, Way et al. (32) reported an increase of connective tissue growth factor expression in the myocardium of diabetic PKC␤2 Tg mice, and associated this with the induction of cardiac fibrosis and dysfunction.
The PKC family is traditionally divided into the following three subgroups: the classic or conventional (␣, ␤1, ␤2, ␥), the novel (␦, ε, , and ) and the atypical (, , , and ). Several of these PKC isoforms may play a crucial role in the signaling pathways involved with both pathological and physiological hypertrophy (7) . Members of the classic group, specifically PKC␣ and ␤, have been widely studied for their role in the cardiovascular system and act similarly by translocating from cytosol to membrane by the induction of ANG II, an oligopeptide known to cause vasoconstriction and increased blood pressure in vivo as well as cellular hypertrophy in vitro (14, 19, 26) . PKC␣, one of the more widely studied isoforms, has been identified as a regulator of cardiac contractility and calcium handling in cardiomyocytes, although it has not been shown to directly affect the hypertrophic growth response of the adult heart (3). We found that the decreased cardiac function exhibited by PKC␤2 mice was rescued when they were crossed with caPI3-kinase mice. In turn, crossing PKC␤2 with dnPI3-kinase mice (dnPI3-kinase/PKC␤2) did not improve cardiac function compared with PKC␤2 mice. Of note, the PKC␤2 mice used in this study originated in a Tg mouse line with a less significant phenotype than the Tg line originally reported (30) . Nevertheless, this PKC␤2 Tg line is also characterized by a significant increase in cardiac fibrosis and cardiac dysfunction compared with WT mice. Our observations revealed that the cardiac dysfunction associated with increased PKC␤2 expression can be improved by an increase in PI3-kinase activity.
Our findings reveal the potential existence of an interaction between PI3-kinase and PKC␤2, either directly or indirectly, through a downstream target of the PI3-kinase pathway. We found that PKC␤2 expression is attenuated significantly by the activation of PI3-kinase, indicating that PI3-kinase may inhibit protein expression levels of PKC␤2, thus explaining the attenuation of the pathological characteristics of PKC␤2 mice in caPI3-kinase/PKC␤2 mice. Although an interaction of PKC and PI3-kinase has been demonstrated previously (27) , the present study is the first to demonstrate that PKC␤2 is regulated by PI3-kinase activation. In fact, downregulation of PI3-kinase in dnPI3-kinase/PKC␤2 double-Tg mice did not affect the expression of PKC␤2 protein, suggesting that PI3-kinase is a negative regulator of PKC␤2.
Our data infer that PI3-kinase is an upstream regulator of PKC␤2, since PKC␤2 does not appear to change the protein levels of downstream targets of PI3-kinase. One of the possible downstream targets of PI3-kinase that may mediate its effect on PKC␤2 is Akt. Akt, which is activated by both receptor tyrosine kinases/cytokines (4, 8) and G protein-coupled receptors (5, 6) , is a likely potential mediator of PKC␤2 protein level in mammalian cells, since it has been shown to regulate other downstream targets of PI3-kinase such as P70 S6K1 and glycogen synthase kinase (GSK-3) (10, 15) . In previously published data, Akt was found to regulate GSK-3␤, which was identified as negatively modulating cardiomyocyte hypertrophy as well as mediating cardioprotection postischemia-reperfusion injury (12, 34) . In turn, we found that Akt activity was increased in caPI3-kinase and caPI3-kinase/PKC␤2 mice.
Studying lipid kinases involved in signal-transduction cascades that mediate cardiac protection and cellular growth may provide insight into potential interventions for heart failure. We have demonstrated that cross talk between PI3-kinase and PKC␤2 pathways enables the pathological characteristics of PKC␤2 mice to be attenuated in caPI3-kinase/PKC␤2 mice. Further studies are required to determine the specific interactions between the PI3-kinase pathway and PKC isoforms, as well as the intermediary molecules involved.
